Mechanism of Action.
Kisspeptin-10 is the minimal bioactive fragment of the full-length kisspeptin-54 neuropeptide, retaining the C-terminal 10 amino acids essential for receptor binding. It activates the KISS1 receptor (GPR54) on GnRH neurons in the hypothalamus, triggering the release of gonadotropin-releasing hormone. GnRH then stimulates the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In males, the resulting LH surge stimulates Leydig cell testosterone production. Kisspeptin signaling acts as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, making it a more physiologically upstream target than GnRH analogs or direct testosterone supplementation.
Research Summary.
Clinical research has demonstrated that kisspeptin potently stimulates LH and testosterone in both men and women. Studies at Imperial College London showed that kisspeptin-54 infusion in healthy men produced significant LH and testosterone elevation. The shorter kisspeptin-10 fragment retains full receptor binding activity with rapid onset but shorter duration. Research has explored kisspeptin for hypogonadotropic hypogonadism, IVF optimization, sexual arousal (kisspeptin activates limbic brain regions associated with attraction), and as a diagnostic tool for HPG axis assessment. A 2017 study in the Journal of Clinical Investigation showed that kisspeptin enhanced brain processing of sexual and emotional stimuli in men.
Side Effects & Safety.
Kisspeptin-10 has shown a favorable safety profile in clinical studies with no serious adverse events reported. The main limitation is its very short half-life (~28 minutes), requiring frequent dosing or continuous infusion for sustained effect. Potential concerns include gonadotropin desensitization with continuous high-dose exposure (similar to GnRH agonist downregulation) and the theoretical possibility of precocious puberty effects in adolescents. As a research compound, long-term safety data from chronic administration is limited.
Legal Status & Access.
Kisspeptin-10 is classified as a Category 1 research peptide. It is not FDA-approved for any clinical indication. It is available from peptide research suppliers for laboratory investigation. It is not a controlled substance.